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ments and supports the feasibility of this approach. CONCLUSIONS: This novel
design seeks to address the bias inherent in observational research through the
imposition of randomization. By separating data collection into a preliminary
phase collecting only variables needed for treatment identification and random-
ization and a separate full review of only these randomly-selected patient records,
chart abstraction burden is minimized. Furthermore, the use of propensity score
matching to create two matched cohorts for comparison allows greater control of
potential confounding in analyses of treatment effect.
SB4
A METHODOLOGY FOR ASSESSING TREATMENT EFFECT IN THE PRESENCE OF
DISEASE SEVERITY AND COMORBIDITY IN RETROSPECTIVE OBSERVATIONAL
STUDIES
Kiri VA
PAREXEL International, Uxbridge, London, UK
OBJECTIVES: There are many examples in health outcomes research where inad-
equate control for comorbidity influence has resulted in effect estimates con-
founded by disease severity. Selection bias is a common feature of data from rou-
tine healthcare settingwhere the decision to give a particular drug to a patientwith
a given disease is generally based on patient characteristics, including disease
condition. Thus, failure to properly control for the bias could result in false associ-
ations. Propensity scores methodology is commonly used despite its limitations
because of its potential for minimising the association between exposure and con-
founding factors. We describe a methodology for assessing drug effect in longitu-
dinal data that minimises confounding by disease severity generally associated
with observational studies. METHODS: For a particular outcome of interest, we
obtain the profiles of rates ratios from two sets of matched cohorts. In set A, pa-
tients with disease X are compared with others free of X in the periods prior to and
post diagnosis of X. In set B which involves only patients with disease X, those
exposed to treatment Y are compared with those unexposed to the drug in the
periods prior to and post exposure. The two sets of profiles are then assessed using
simple regression over the respective periods. In effect, we attempt to disentangle
the disease and treatment effects. Data from the UK GPRD are used to assess
possible association between a particular outcome and treatment in COPD
RESULTS: We found evidence of association between the outcome and COPD but
none for the drug. CONCLUSIONS: The profile approach utilizes the data collected
over the disease natural history and exposure history to assess the relationships
between the outcome and both the disease and treatment. This is a key strength
often ignored when results are reported as point estimates. By design, it also mi-
nimises the effect of selection bias.
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OBJECTIVES: Advanced sensitivity methods including value of information were
developed to quantify overall decision uncertainty and to assess the cost-effective-
ness of additional research that would reduce that uncertainty. Our objective was
to compare the information gained by utilizing three alternative sensitivity meth-
ods with increasing complexity: a simple one-way sensitivity analysis; probabilis-
tic analysis of covariance (ANCOVA); and expected value of partial perfect infor-
mation (EVPPI) of input parameters. METHODS: We replicated and expanded a
published HIV/AIDS cost-effectiveness Markov model (zidovudine vs. zidovudine
plus lamivudine in the UK) using TreeAge®. Health states included three HIV/AIDS
states and death. Our outcome of interest was the incremental net monetary ben-
efit (INMB) assuming awillingness-to-pay of £20,000/QALY.We generated one-way
and probabilistic sensitivity analyses of the INMB using published input parameter
uncertainties. One-way sensitivity analysis identified the 10 most influential pa-
rameters. A total of 10,000 Monte Carlo draws were used to estimate the ANCOVA
results from the same ten parameters. EVPPI for each of the same ten parameters
was estimated specifying 1000 inner and 1000 outerMonte Carlo draws.We ranked
the parameters based on their influence on variation for each sensitivity method
and compared themusing Spearman’s rank correlation. RESULTS:Mean INMBwas
£9694 in favor of combination therapy. The two most influential inputs were the
same across all methods, contributed 78% of variation in outcome (ANCOVA), and
were the only inputs with non-zero EVPPI values. The rank order for the top ten
inputs from all methods was similar (correlation0.99 for one-way vs. ANCOVA,
0.70 for one-way vs. EVPPI and 0.70 for ANCOVA vs. EVPPI, all p-values  0.05).
CONCLUSIONS: The correlation was significant between one-way and more ad-
vanced sensitivity analyses. Although each method provides unique information,
the additional resources needed to generate advanced analyses should beweighed,
especially when the outcome decision uncertainty and therefore value of informa-
tion is low.
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OBJECTIVES: In a simulated dataset, evaluate incremental cost-effectiveness ratios
(ICERs) adjusted for covariates and missing data using three different regression
models. The regression parameter of interest is the incremental net monetary
benefit (INMB). Models are ANCOVA, mixed effects (ME), and joint mixed effects
and log time-to-dropout (joint ME), a selectionmodel.METHODS: Traditional cost-
effectiveness analysis (CEA) uses the incremental cost-effectiveness ratio (ICER), a
measurewith statistical issues and limitationswithmissing data. Regression anal-
ysis can estimate incremental net monetary benefit (INMB) and avoid these statis-
tical issues while adjusting for covariates as well as missing data. The cost-effec-
tiveness acceptability curve (CEAC) generated from a family of these regressions
can identify an ICER adjusted for the factors included in the INMB regressions (the
ICER is the point on the CEAC where the probability of being cost-effective is 50%).
Data were simulated to include missing at random (MAR) and missing not at ran-
dom (MNAR). Simulated treatment effect provided a “true” INMB for model evalu-
ations that included bias (absolute difference from “true”), precision (ratio of vari-
ances), and CEACs with willingness-to-pay () values from $0 to $100K. RESULTS:
TheANCOVA andMEmodels produced the least biased estimates. At  $50K, bias
was $1.3K, $1.4K, and 2.3K, and precision was 1.27, 0.90, and 1.24 for ME, ANCOVA,
and joint ME, respectively. The joint ME model performed best when missingness
was high. CONCLUSIONS: Once the CEACs had been generated, deriving ICERs
adjusted for covariates and missing data from those CEACs based upon INMB re-
gressions proved easy and feasible. The models used in this simulation analysis
performeddifferently under alternativemissingness conditions andwere sensitive
to nonresponsemechanisms. All estimateswere poorwhenmissingnesswas high;
suggesting prevention of missing data should be a goal of research.
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OBJECTIVES: Cost-effectiveness analysis (CEA) has traditionally been seen as a
means of satisfying a specific and explicit social objective subject to a fixed budget
constraint. As a result, existing CEAmethods largely ignore budget impact consid-
erations in health systems where budgets are not fixed. In particular, none of the
traditional methods of presenting results (such as the cost-effectiveness plane,
ICER tables and CEAC graphs) can be used to summarize the results of a CEA and
budget impact assessment simultaneously. Our objective was to develop such a
method in a manner which is meaningful to decision makers. METHODS: We
present a novel way of combining cost-effectiveness and budget impact consider-
ations into a single graph. To do this, we disaggregate the incremental costs of the
new technology into those which fall on the health budget and displace other
technologies (resulting in forgone health) and those which lead to an expansion of
the health budget (resulting in a net budget impact). The incremental health ben-
efit of the technology and any forgone health are combined to give the net health
benefit of the technology,which is plotted against the net budget impact. RESULTS:
Our method clearly reveals the trade-off between the cost-effectiveness and
budget impact of the technology in question. This trade-off is simultaneously re-
vealed across a range of plausible values of the cost-effectiveness threshold.
CONCLUSIONS: Decision makers who are concerned with both the cost-effective-
ness and budget impact of new technologies have tended to consider each of these
separately, with the inherent trade-off between the two blurred in the process. Our
proposed method makes this trade-off explicit and does so across a range of
threshold values, enabling analysts to provide meaningful information to decision
makers while respecting decision makers’ authority in determining the appropri-
ate threshold to use.
CE4
USING DYNAMIC TRANSMISSION MODELS TO ESTIMATE THE COST
EFFECTIVENESS OF VACCINES: FOUR DIFFERENT METHODS AND THEIR
RELEVANCE FOR DECISION MAKERS
Mauskopf J1, Talbird SE1, Standaert B2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline Biologicals, Wavre,
Belgium
OBJECTIVES: To compare the differences in the methods used to estimate the
cost-effectiveness of vaccination programs using the clinical outcomes from dy-
namic transmission models. METHODS: A targeted electronic literature search of
title words in the PubMed databases was performed to identify studies published
since 2000 that included a description of themethods and presentation of results of
cost-effectiveness analysis of vaccination programs based on data from dynamic
transmission models for any infectious disease. Further studies were identified in
the bibliographies of the initial set of papers.RESULTS: Informationwas abstracted
from 29 papers presenting cost-effectiveness analyses of vaccination programs for
influenza, HPV, varicella virus, pertussis, meningococcal meningitis, rotavirus, H.
pylori, and hepatitis A. Both cohort and population-based estimates of cost-effec-
tiveness were presented. The population-based estimates had variable time hori-
zons from 1 year for influenza or pertussis (the steady state year) up to 100 years for
HPV, varicella, and meningococcal vaccination. All cohort analyses used a lifetime
time horizon. Four method types for the estimation and presentation of a cost-
effectiveness ratio were identified: 1) average population values (costs and bene-
fits) over a long time horizon assuming a continuing vaccination program (20 pa-
pers) 2) average population values over a long time horizon assuming a limited
duration vaccination program (1 paper) 3) population values for the steady-state
year only (1 paper) and 4) cohort values with a lifetime horizon (7 papers).
CONCLUSIONS: The variability of the estimation framework (population or cohort)
and time horizon used aswell as the variability in other input parameters observed
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